Growth Hormone and Heart Failure: Implications for Patient Stratification, Prognosis, and Precision Medicine

被引:3
|
作者
Theodorakis, Nikolaos [1 ,2 ,3 ]
Kreouzi, Magdalini [4 ]
Hitas, Christos [3 ]
Anagnostou, Dimitrios [3 ]
Nikolaou, Maria [3 ]
机构
[1] Clin Metab & Athlet Performance, NT Cardiometab, Palaio Faliro 17564, Greece
[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens 11527, Greece
[3] Sismanogleio Amalia Fleming Gen Hosp, Dept Cardiol, Melissia 15127, Greece
[4] Sismanogleio Amalia Fleming Gen Hosp, Dept Internal Med, Melissia 15127, Greece
关键词
growth hormone; insulin-like growth factor-I; heart failure; anabolic hormones; multiple hormonal deficiency syndrome; randomized controlled trials; precision medicine; LEFT-VENTRICULAR FUNCTION; HUMAN GH THERAPY; EXERCISE CAPACITY; PERFORMANCE; DEFICIENCY;
D O I
10.3390/diagnostics14242831
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure (HF) remains a major cause of morbidity and mortality worldwide. While standard treatments primarily target neurohormonal pathways, emerging evidence highlights the significant role of hormonal deficiencies, such as impaired growth hormone (GH) signaling, in HF progression and outcomes. GH is crucial for cardiovascular and skeletal muscle function, and its deficiency has been associated with worse prognosis. This review synthesizes recent findings from randomized controlled trials (RCTs) to explore how GH can contribute to personalized care and improve patient stratification in HF. A comprehensive literature review was conducted using PubMed up to 10 October 2024. Search terms included "growth hormone" combined with "heart failure", "HFrEF", "HFpEF", and "HFmrEF." Only placebo-controlled RCTs published in English and involving human subjects were considered. Data on study design, participant characteristics, GH dosing, and key clinical outcomes were systematically extracted and analyzed. Several trials demonstrated that GH therapy can transiently improve left ventricular ejection fraction (LVEF), exercise capacity, and reduce inflammatory markers. For example, one study has reported an increase in LVEF from 32 +/- 3.8% to 43.8 +/- 4.6% (p = 0.002), following three months of GH therapy in post-MI HF patients. However, benefits diminished after discontinuation. Additional studies have observed sustained improvements in peak oxygen consumption and LVEF over four years, with an additional trend towards hard endpoint improvement. Conversely, some studies showed no significant impact on cardiac function, highlighting heterogeneity in outcomes. As a result, GH therapy holds promise for improving cardiac and functional parameters in HF patients, but evidence remains mixed. Larger, long-term RCTs are needed to confirm its efficacy and safety. Precision medicine approaches and biomarker-driven strategies may optimize patient outcomes and guide clinical practice.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Growth hormone therapy in heart failure
    O. Strohm
    M.G. Friedrich
    R. v. Harsdorf
    K.-J. Osterziel
    R. Dietz
    Zeitschrift für Kardiologie, 1999, 88 (Suppl 3): : S040 - S046
  • [22] Growth Hormone as Biomarker in Heart Failure
    Marra, Alberto M.
    Bobbio, Emanuele
    D'Assante, Roberta
    Salzano, Andrea
    Arcopinto, Michele
    Bossone, Eduardo
    Cittadini, Antonio
    HEART FAILURE CLINICS, 2018, 14 (01) : 65 - +
  • [23] Precision Medicine for Heart Failure Lessons From Oncology
    Feldman, Arthur M.
    Kontos, Christopher D.
    McClung, Joseph M.
    Gerhard, Glenn S.
    Khalili, Kamel
    Cheung, Joseph Y.
    CIRCULATION-HEART FAILURE, 2017, 10 (06)
  • [24] Sex differences in heart failure and precision medicine: right patient, right time ... wrong dose?
    Hassan, Rana
    Ahmed, Sofia B.
    HEART, 2021, 107 (21) : 1692 - 1693
  • [25] The role of biomarkers in the prognosis and risk stratification in heart failure: A systematic review
    Singh, Gurmehar
    Bamba, Hyma
    Inban, Pugazhendi
    Chandrasekaran, Sai Harini
    Priyatha, Vemparala
    John, Jobby
    Prajjwal, Priyadarshi
    DM DISEASE-A-MONTH, 2024, 70 (10):
  • [26] Prognosis and Risk Stratification of Patients With Advanced Heart Failure (from PROBE)
    Cameli, Matteo
    Pastore, Maria Concetta
    Mandoli, Giulia E.
    Nistor, Dan
    Lisi, Edoardo
    Tok, Ozge O.
    Cavigli, Luna
    Romano, Andrea
    Mondillo, Sergio
    AMERICAN JOURNAL OF CARDIOLOGY, 2019, 124 (01): : 55 - 62
  • [27] Prognosis in Heart Failure: A TNM-Like Classification for Risk Stratification
    Alfarano, Maria
    Severino, Paolo
    Pucci, Mariateresa
    Mancini, Ilaria
    Ferrari, Ilaria
    Peroni, Stefano
    Calcagno, Simone
    Fusto, Antonio
    Fegatelli, Danilo Alunni
    Vestri, Annarita
    Sciomer, Susanna
    Mancone, Massimo
    Fedele, Francesco
    CIRCULATION, 2017, 136
  • [28] A decision support system in precision medicine: contrastive multimodal learning for patient stratification
    Yin, Qing
    Zhong, Linda
    Song, Yunya
    Bai, Liang
    Wang, Zhihua
    Li, Chen
    Xu, Yida
    Yang, Xian
    ANNALS OF OPERATIONS RESEARCH, 2023,
  • [29] MediBoost: a Patient Stratification Tool for Interpretable Decision Making in the Era of Precision Medicine
    Gilmer Valdes
    José Marcio Luna
    Eric Eaton
    Charles B. Simone
    Lyle H. Ungar
    Timothy D. Solberg
    Scientific Reports, 6
  • [30] MediBoost: a Patient Stratification Tool for Interpretable Decision Making in the Era of Precision Medicine
    Valdes, Gilmer
    Luna, Jose Marcio
    Eaton, Eric
    Simone, Charles B., II
    Ungar, Lyle H.
    Solberg, Timothy D.
    SCIENTIFIC REPORTS, 2016, 6